Helping projects
change the future
APPLY NOW

News

Case in point: Botkin AI analyzing CT scans for cancer detection

3 July 2019

Sergei Sorokin, the founder of Botkin AI project, a Primer Capital's portfolio unit, and an expert in IT solutions for medicine shared his views on AI within Russian healthcare system with HighTech

Case in point: Botkin AI analyzing CT scans for cancer detection

Sergei Sorokin, the founder of Botkin AI project, a Primer Capital's portfolio unit, and an expert in IT solutions for medicine shared his views on AI within Russian healthcare system with HighTech
 

Botkin.AI, an AI medical platform, raised 100 million rubles in investment

3 June 2019

Botkin.AI, Primer Capital’s portfolio unit, raised a round A of investments for the development of the artificial intelligence (AI) platform for cancer detection.

Botkin.AI, an AI medical platform, raised 100 million rubles in investment

Botkin.AI, Primer Capital’s portfolio unit, raised a round A of investments for the development of the artificial intelligence (AI) platform for cancer detection.
 

Head of Primer Capital to choose among the best pharmaceutical and medical projects

27 May 2019

Application period for the Startup Rally competition initiated by the Ministry of Industry and Trade of Russia ends June 1, 2019. Primer Capital COO Elizaveta Rozhdestvenskaya, as one of the judges, will be evaluating the projects of teams working on the development of new drugs, diagnostic test systems and medical products.

Head of Primer Capital to choose among the best pharmaceutical and medical projects

Application period for the Startup Rally competition initiated by the Ministry of Industry and Trade of Russia ends June 1, 2019. Primer Capital COO Elizaveta Rozhdestvenskaya, as one of the judges, will be evaluating the projects of teams working on the development of new drugs, diagnostic test systems and medical products.
 

Primer Capital Partners with an accelerator by AstraZeneca and Skolkovo

7 May 2019

Primer Capital, the leading Russian pharma and biotech venture fund, partnered with the acceleration program launched by AstraZeneca and Skolkovo Foundation.

Primer Capital Partners with an accelerator by AstraZeneca and Skolkovo

Primer Capital, the leading Russian pharma and biotech venture fund, partnered with the acceleration program launched by AstraZeneca and Skolkovo Foundation.
 

Survival course. Breakthrough development of cell products and technologies for target treatment of cancer

25 April 2019

New cell products and technologies breakthroughs for targeted cancer therapy can dramatically change therapy prognosis for thousands of patients.
On April 24, within the Skolkovo StartUp Tour 2019 in Novosibirsk, Primer Capital and the Novosibirsk innovation company ECAR signed an agreement with the intention to collaborate on the development of cellular therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Survival course. Breakthrough development of cell products and technologies for target treatment of cancer

New cell products and technologies breakthroughs for targeted cancer therapy can dramatically change therapy prognosis for thousands of patients.
On April 24, within the Skolkovo StartUp Tour 2019 in Novosibirsk, Primer Capital and the Novosibirsk innovation company ECAR signed an agreement with the intention to collaborate on the development of cellular therapy for the treatment of metastatic hormone-sensitive prostate cancer.
 

Multiple myeloma drug developer has become a resident of the research lab space CoLaborator® by Bayer

19 April 2019

Hemofarm, a startup and the developer of a biotech drug for patients diagnosed with multiple myeloma and non-Hodgkin's lymphoma, has become a resident at the Bayer innovation research lab CoLabrator®.

Multiple myeloma drug developer has become a resident of the research lab space CoLaborator® by Bayer

Hemofarm, a startup and the developer of a biotech drug for patients diagnosed with multiple myeloma and non-Hodgkin's lymphoma, has become a resident at the Bayer innovation research lab CoLabrator®.
 

Acticor's blood thinner cuts hemorrhage risk in human study

19 April 2019

The new compound, called ACT017, developed by Primer Capital portfolio project, French startup Acticor Biotech in a phase 1 study on healthy volunteers showed it could inhibit clot formation without prolonging bleeding time. It is a marker that indicates increased risk of hemorrhage, according to results published in Arteriosclerosis, Thrombosi and Vascular Biology, an American Heart Association journal.

Acticor's blood thinner cuts hemorrhage risk in human study

The new compound, called ACT017, developed by Primer Capital portfolio project, French startup Acticor Biotech in a phase 1 study on healthy volunteers showed it could inhibit clot formation without prolonging bleeding time. It is a marker that indicates increased risk of hemorrhage, according to results published in Arteriosclerosis, Thrombosi and Vascular Biology, an American Heart Association journal.
 

Boosting the competitiveness of the Russian pharma biotech

16 April 2019

Primer Capital, Tatchempharmpreparaty JSC and Kazan Federal University (KFU) are to launch a new innovative pharma project to cure epilepsy.
On April 11, during the Russian Venture Forum in Kazan, Primer Capital, Tatchempharmpreparaty JSC and KFU signed a term-sheet to join their efforts on developing an anti-epileptic drug.

Boosting the competitiveness of the Russian pharma biotech

Primer Capital, Tatchempharmpreparaty JSC and Kazan Federal University (KFU) are to launch a new innovative pharma project to cure epilepsy.
On April 11, during the Russian Venture Forum in Kazan, Primer Capital, Tatchempharmpreparaty JSC and KFU signed a term-sheet to join their efforts on developing an anti-epileptic drug.
 

Head of Primer Capital spoke at the Russian Venture Forum

15 April 2019

On April 11th, 2019, one the largest investment conferences in Eurasia, the Russian Venture Forum took place in Kazan. Alongside the representatives of I2BF Global Ventures, Skolkovo, Tatneft, Sberbank, Larix, Starta Capital, Vnesheconombank, Primer Capital COO Elizaveta Rozhdestvenskaya took part in the panel discussion dedicated to the collective investment models.

Head of Primer Capital spoke at the Russian Venture Forum

On April 11th, 2019, one the largest investment conferences in Eurasia, the Russian Venture Forum took place in Kazan. Alongside the representatives of I2BF Global Ventures, Skolkovo, Tatneft, Sberbank, Larix, Starta Capital, Vnesheconombank, Primer Capital COO Elizaveta Rozhdestvenskaya took part in the panel discussion dedicated to the collective investment models.
 

Primer Capital to choose the best biomed startups at Start Up Tour

11 April 2019

Primer Capital team of experts was invited to judge the participants at the “Biotech in medicine and agriculture” contest within the Start Up Tour which started on February 5th in Kemerovo and will go on until April 24th.

Primer Capital to choose the best biomed startups at Start Up Tour

Primer Capital team of experts was invited to judge the participants at the “Biotech in medicine and agriculture” contest within the Start Up Tour which started on February 5th in Kemerovo and will go on until April 24th.

Записи 11 - 20 of 55
First | Prev. | 1 2 3 4 5 | Next | Last